Study title: Vecchi-V, Pileri-S, Burnelli-R, Bontempi-N, Comelli-A, Testi-A-M, Carli-M, Sotti-G, Rosati-D, Di-Tullio-M-T, et al. III Department of Pediatrics, Bologna University, Italy. Treatment of pediatric Hodgkin disease tailored to stage, mediastinal mass, and age. An Italian (AIEOP) multicenter study on 215 patients. Cancer, {Cancer}, 15 Sep 1993, vol. 72, no. 6, p. 2049-57, ISSN: 0008-543X.Vecchi-V, Pileri-S, Burnelli-R, Bontempi-N, Comelli-A, Testi-A-M, Carli-M, Sotti-G, Rosati-D, Di-Tullio-M-T, et al. III Department of Pediatrics, Bologna University, Italy. Treatment of pediatric Hodgkin disease tailored to stage, mediastinal mass, and age. An Italian (AIEOP) multicenter study on 215 patients. Cancer, {Cancer}, 15 Sep 1993, vol. 72, no. 6, p. 2049-57, ISSN: 0008-543X.
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Neoplasms [C04] | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: PROCARBAZINE | |||||
| ATC code: | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | - | |